Eficacia de la vacuna contra el virus de la hepatitis B en pacientes con enfermedad inflamatoria intestinal

Pérez, Luis Vida; Camacho, Francisco Gómez; Sánchez, V. García; Flores, E. Marquez; Molina, Laura Castillo; Ruíz, Ana Cristina; Juanena, Luis Casais; Vega, Juan Francisco

doi:10.1016/j.medcli.2008.07.013

Cited by 46 publications

(12 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is possible to observe the effect of age on immune response when examining the outcomes of HBV vaccination in both in healthy populations and IBD groups. 12 , 20 Population-based studies generally indicate <40 years age group as the age group with better vaccine responses, while in an IBD study, the average age was 41 years in the group with vaccine response. 21 , 22 In our series, the average age of the group with vaccine response was 37.3 years, and the cut-off value was 45 years for the age limit that is a determinant for vaccine response.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of Factors Associated With Response to Hepatitis B Vaccination in Patients With Inflammatory Bowel Disease

et al. 2015

View full text Add to dashboard Cite

It is recommended to investigate the serology of hepatitis B virus (HBV) and vaccinate seronegative patients at the time of diagnosis in inflammatory bowel diseases (IBD). This study aimed to investigate the efficacy of HBV vaccine and factors affecting the response.In this retrospective, observational study, HBV-seronegative IBD patients were administered 3 doses (at months 0, 1, and 6) recombinant 20 μg HbsAg. Patients’ demographics, IBD attributes, and treatment methods were investigated as the factors with potential impacts on vaccination outcomes.One hundred twenty-five patients with IBD were evaluated. The number of patients with Anti-HBs >10 IU/L was 71 (56.8%), and the number of patients with anti-HBs >100 IU/L was 50 (40%). Age, disease activity, Crohn disease subtype, and immunosuppressive treatment (IST) were found to have significant effects on immune response (P = 0.011, P < 0.001, P = 0.003, and P < 0.001, respectively). With multivariate analysis, age < 45 years (OR 3.1, 95% CI 1.2–8.3, P = 0.020), vaccination during remission (OR 5.6, 95% CI 2.3–14, P < 0.001), and non-IST (OR 11.1, 95% CI 2.9–43.2, P = 0.001) had favorable effects on the occurrence of adequate vaccine response.The likelihood of achieving adequate immune response with standard HBV vaccination protocol in IBD is low. Selecting vaccination protocols with more potent immunogenicity is a better approach to achieve effective vaccine response in patients with multiple unfavorable factors.

show abstract

Section: Discussionmentioning

confidence: 99%

“… 10 , 11 Although several factors have been suggested to explain this, IBD itself and the increasingly popular use of immunosuppressive treatments (ISTs) are considered the major reasons. 12 – 14 …”

Section: Introductionmentioning

confidence: 99%

Evaluation of Factors Associated With Response to Hepatitis B Vaccination in Patients With Inflammatory Bowel Disease

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Older age and anti-TNF therapy are strongly associated with low response rates to hepatitis B vaccination [16,40]. In a study of 129 IBD patients, Vida Perez et al found that nearly two thirds of the patients had a suboptimal serological response after HBV vaccination, with older patients showing a lower response rate than younger patients (30.91 vs. 39.91, P<0.001) [40].…”

Section: Vaccinationsmentioning

confidence: 99%

“…In a study of 129 IBD patients, Vida Perez et al found that nearly two thirds of the patients had a suboptimal serological response after HBV vaccination, with older patients showing a lower response rate than younger patients (30.91 vs. 39.91, P<0.001) [40]. Another study also noted a lower response rate to HBV vaccination in older IBD patients (OR 0.96, P<0.001).…”

Section: Vaccinationsmentioning

confidence: 99%

Healthcare maintenance in elderly patients with inflammatory bowel disease

Shrestha

Taleban

2016

aog

View full text Add to dashboard Cite

The increasing number of older patients (age ≥60 years) with inflammatory bowel disease (IBD) highlights the importance of healthcare maintenance in this vulnerable population. Older IBD patients are more susceptible and have higher rates of many disease- and treatment-related adverse effects. Compared to younger IBD patients, older patients are at increased risk for infection, malignancy, bone disease, eye disease, malnutrition and thrombotic complications. Preventive strategies in the elderly differ from those in younger adults and are imperative. Changes to the immune system with aging can decrease the efficacy of vaccinations. Cancer screening guidelines in older IBD patients have to account for unique considerations, such as life expectancy, functional performance status, multimorbidity, financial status, and patient desires. Additionally, providers need to be vigilant in screening for osteoporosis, ocular disease, depression, and adverse events arising from polypharmacy.

show abstract

“…In addition, there are specific segments of the population that are poor or non-responders. Among them are the elderly, obese individuals, HIV-positive patients, and individuals with celiac disease, irritable bowel disease, Down syndrome, or chronic kidney disease [5][6][7][8][9][10][11][12][13][14][15]. Therefore, a more effective vaccine may alleviate some of these problems.…”

Section: Introductionmentioning

confidence: 99%

Co-Administration of Injected and Oral Vaccine Candidates Elicits Improved Immune Responses over Either Route Alone

et al. 2020

View full text Add to dashboard Cite

Infectious diseases continue to be a significant cause of morbidity and mortality, and although efficacious vaccines are available for many diseases, some parenteral vaccines elicit little or no mucosal antibodies which can be a significant problem since mucosal tissue is the point of entry for 90% of pathogens. In order to provide protection for both serum and mucosal areas, we have tested a combinatorial approach of both parenteral and oral administration of antigens for diseases caused by a viral pathogen, Hepatitis B, and a fungal pathogen, Coccidioides. We demonstrate that co-administration by the parenteral and oral routes is a useful tool to increase the overall immune response. This can include achieving an immune response in tissues that are not elicited when using only one route of administration, providing a higher level of response that can lead to fewer required doses or possibly providing a better response for individuals that are considered poor or non-responders.

show abstract

Eficacia de la vacuna contra el virus de la hepatitis B en pacientes con enfermedad inflamatoria intestinal

Cited by 46 publications

References 21 publications

Evaluation of Factors Associated With Response to Hepatitis B Vaccination in Patients With Inflammatory Bowel Disease

Evaluation of Factors Associated With Response to Hepatitis B Vaccination in Patients With Inflammatory Bowel Disease

Healthcare maintenance in elderly patients with inflammatory bowel disease

Co-Administration of Injected and Oral Vaccine Candidates Elicits Improved Immune Responses over Either Route Alone

Contact Info

Product

Resources

About